drugset / Trial / NCT07831122
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
Phase 1
Not yet recruiting
108 enrolled
Canadian Myeloma Research Group
GlaxoSmithKline · collabHoffmann-La Roche · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will evaluate efficacy and tolerability various doses of belantamab mafodotin in combination with cevostamab and pomalidomide in patients with multiple myeloma who have relapsed disease after two or more lines of therapy and/or have refractory to treatment disease.
Timeline
- Start
- 2026-12
- Primary completion
- 2033-01
- Completion
- 2033-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belantamab mafodotin | Monoclonal antibody | 1.9 mg/kg | Intravenous |
| Subject | Belantamab mafodotin | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | Cevostamab | Monoclonal antibody | 90 mg | Intravenous |
| Subject | Cevostamab | Monoclonal antibody | 160 mg | Intravenous |
| Subject | Pomalidomide | Other / unclassified | 2 mg | Oral |